Vaccination with IL-7 Gene-Modified Melanoma Cells
Author Information
Author(s): P Moller, Y Sun, T Dorbic, S Alijagic, A Makkil, K Jurgovsky, M Schroff, B M Henz, B Wittig, D Schadendorf
Primary Institution: Universitatshautklinik, Virchow Klinikum, Humboldt-Universitat zu Berlin
Hypothesis
Can vaccination with IL-7 gene-modified autologous melanoma cells enhance anti-melanoma immune responses in patients?
Conclusion
Vaccination with gene-modified autologous melanoma cells induced immunological changes, suggesting an increased anti-tumor immune response, particularly in patients with good physical condition.
Supporting Evidence
- Eight out of ten patients completed the initial vaccinations and were evaluated for immune response.
- Three of six patients showed a significant increase in anti-melanoma cytolytic precursor cells.
- Immunological changes were most pronounced in patients with good physical condition.
Takeaway
Doctors tested a new vaccine made from patients' own cancer cells to see if it could help their immune system fight melanoma, but it didn't work as well as hoped.
Methodology
Ten patients with advanced melanoma received vaccinations with their own IL-7 gene-modified melanoma cells, and their immune responses were monitored.
Potential Biases
Potential bias due to the lack of a control group and the small number of patients.
Limitations
The study had a small sample size and lacked a control group, making it difficult to draw definitive conclusions.
Participant Demographics
Patients had advanced metastatic melanoma and varied in age and previous treatments.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website